Should you buy these beaten down ASX shares?

In the last three months the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has had a reasonably disappointing time and fallen approximately 1.2%.

Unfortunately this decline is nothing compared to what some shares on the index have endured. The two shares below have fallen especially hard during this time. Will they bounce back?

The Myer Holdings Ltd (ASX: MYR) share price has fallen 29% in the last three months due to weak trading conditions and concerns over the impact Amazon will have on its business. While data released yesterday by the ABS revealed that Australian retail sales improved in May ahead of expectations, sales in the department stores category once again declined. Whilst Myer’s shares are arguably dirt cheap at 9x trailing earnings, I do have concerns that this could ultimately prove to be a value trap. For this reason I would stay clear of the retailer no matter how tempting it is.

The Sigma Healthcare Ltd (ASX: SIG) share price has tumbled 30% during the last three months. The catalyst for this decline was the pharmacy wholesale and distribution company’s decision to take legal action against one of its biggest customers. Sigma was forced to take legal action after The My Chemist/Chemist Warehouse Group advised of its plan to source certain products from a different supplier. Doing so would impact Sigma’s EBIT by between $5 million and $10 million per year according to management. Whilst this is bad, my biggest concern is that its contract with MC/CW expires in 2019. At this stage I feel it is very unlikely that it will be renewed, leaving Sigma with a sizeable gap in its future earnings. Because of this I would hold off an investment.

Instead of investing in Myer or Sigma, I would suggest investors take a look at this quality dividend share.

1 Massive Dividend Stock to Buy Today

FREE REPORT! Click here to discover the Motley Fool's #1 ASX dividend recommendation

You may not know the name of this market leader, but it's making waves in Asia and already boasts a term-deposit-crushing dividend of almost 5%. So what's not to like?

Simply click here to grab your free copy of this up-to-the-minute research report right now.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.